Patent ID: 9422366
Filing Date: 2016-08-23
CPC Classification: A61P,C07K

Claim Text:
1. A method of treating a human TNFα-mediated disease in a subject, comprising administering to a subject an antibody that specifically binds human TNFα such that the subject is treated for the TNFα-mediated disease, wherein the antibody comprises: (a) a human heavy chain variable framework sequence and CDR H1, CDR H2 and CDR H3 sequences, wherein the human heavy chain variable region framework has at least 90% identity to SEQ ID NO:2 and the CDR H1, H2, and H3 sequences are the sequences of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, respectively; and (b) a human light chain variable framework sequence and CDR L1, CDR L2 and CDR L3 sequences, wherein the human light chain variable region framework sequence has at least 85% identity to SEQ ID NO: 1 and the CDR L1, L2, and L3 sequences are the sequences of SEQ ID NO: 36, SEQ ID NO: 37 and SEQ ID NO: 38, respectively.